dm+d

25965211000001106

Refrigerated Storage

MekinistNovartis Pharmaceuticals

Novartis Pharmaceuticals
Mekinist
0.5 mg and 2 mg tablets

In the event of an inadvertent temperature excursion the following data may be used:

The product can be stored at temperatures ≤30°C for 30 days.
Please also refer to the manufacturer’s product literature for recommended storage information at https://www.medicines.org.uk

26 January 2022
London MI Service

New Medicines

Mekinist BRAF V600 mutation positive low grade glioma (LGG) or high grade glioma (HGG) in children - with dabrafenib

Information

Mekinist
Licence extension / variation
Novartis
Novartis

Development and Regulatory status

Phase II Clinical Trials
Phase II Clinical Trials
Phase II Clinical Trials
Yes
Yes

Category

MEK inhibitor, given in combination with a BRAF inhibitor (dabrafenib)
In the UK, brain tumours occur in about 5 per 100,000 of children between the ages of 0-9 years. The largest subgroup is astrocytoma, a type of glioma (43% of all brain and CNS tumours in children). Astrocytomas are diagnosed throughout childhood. 76% of astrocytomas are diagnosed as low-grade and 15% as high-grade [1].
BRAF V600 mutation positive low grade glioma (LGG) or high grade glioma (HGG) in children - with dabrafenib
Oral